DDM-006 - Enhancing targeted liver fibrosis therapy: Evaluating retinol-modified nanoparticles for Activated Hepatic Stellate Cells targeting and assessing atorvastatin- and JQ1-loaded NPs for effective aHSC deactivation

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: DDM-006
• By: EZZAT, Aya (German University In Cairo-GUC, Egypt)
• Co-author(s): Dr Aya Ezzat (German University In Cairo-GUC, Cairo , Egypt)
  Prof Samar Mansour (German University In Cairo-GUC, Cairo , Egypt)
  Dr Salma Tammam (German University In Cairo-GUC, Cairo , Egypt)
  
• Abstract:

  Background: Fibrotic diseases impose a substantial burden on healthcare systems. Liver fibrosis, a precursor to cirrhosis, stands as the 11th most significant contributor to global mortality. While the reversal of liver fibrosis is now considered an attainable objective, the absence of an anti-fibrotic drug in the market remains a significant..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login